The L858R point mutation of exon 21 and a compound T790M EGFR substitution mutation were detected in the tumor cells, which was consistent with the study by Pao et al (23), indicating that the efficacy of EGFR-TKIs in lung cancer is severely compromised by the rapid emergence of targeted therapy-resistant clones within one year. The gene discussed is EGFR; the disease is lung cancer.